Our significant findings provide the first scientific evidence that PRRE treatment effectively alleviates the severity of clinical symptoms of colitis, reduces histopathological damage and infiltration of inflammatory cells in the colon, suppresses pro-inflammatory cytokine productions, and preserves mucin-secreting goblet cells in DSS-induced colonic inflammation in mice. This evidence concerns the gene MUC5AC and colitis.